10-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide

Catalog No. :
ACOLND605
CAS No. :
1401304-15-1
Molecular Formula :
C12H10BrN3O2
Molecular Weight :
308.14

IUPAC Name:10-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide

10-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$675.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name10-Bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
IUPAC Name10-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
MDL No.MFCD29919927
Molecular FormulaC12H10BrN3O2
Molecular Weight308.14
SMILESO=C(C1=CN2CCOC3=CC=C(Br)C=C3C2=N1)N
InChI KeyMFGSOCJEBRAPDJ-UHFFFAOYSA-N
Synonym10-BROMO-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPINE-2-CARBOXAMIDE;Imidazo[1,2-d][1,4]benzoxazepine-2-carboxamide, 10-bromo-5,6-dihydro-
CAS No.1401304-15-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACOLND605 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOLND605 route product structure diagram
    ACOLND6051401304-15-1
Inquiry

2. ACOLND605 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  4. Plus
  5. reactant_3 route compound structure diagram
    --
  6. Then
  7. ACOLND605 route product structure diagram
    ACOLND6051401304-15-1
Inquiry

Comments (0)